Related Experiment Video
Updated: Jun 9, 2025

Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli
Published on: December 26, 2020
Rewiring Lysine Catabolism in Cancer Leads to Increased Histone Crotonylation and Immune Escape
Kosta Besermenji1, Rita Petracca1
1Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, David De Wied building, Universiteitsweg 99, 3584 CG, Utrecht, NL.
Abstract:
Crotonyl-CoA (cr-CoA) is a metabolite derived directly from the catabolism of lysine (Lys) and tryptophan (Trp) or from the β-oxidation of fatty acids. In glioblastoma stem cells (GSCs), histone H4 crotonylation levels are significantly elevated, which appears to positively correlate with tumor growth. This increase in crotonyl-CoA production is attributed to the overexpression of specific Lys transporters on the cell membrane, leading to higher free lysine levels. Additionally, the overexpression of glutaryl-CoA dehydrogenase (GCDH), the enzyme responsible for crotonyl-CoA production, further contributes to this increase. When GCDH is depleted or under a lysine-restricted diet, genes involved in type I interferon (IFN) signaling are upregulated, resulting in tumor growth suppression. Type I interferons are a group of cytokines critical for antiviral responses and immunoregulation. This highlights how cancer cells exploit crotonylation to modulate the immune response. This work opens up new avenues for investigating how cancer cells rewire their metabolism to increase crotonylation and evade the immune system.
More Related Videos
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Spreading of Chromatin Modifications
Writers
The writer...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistant Cancers

